Wegovy works by mimicking a hormone called glucagon-like peptide-1 (GLP-1) that targets areas of the brain that regulate appetite and food intake. The medication dose must be increased gradually over 16 to 20 weeks to 2.4 mg once weekly to reduce gastrointestinal side effects. Wegovy should not be used in combination with other semaglutide-containing products, other GLP-1 receptor agonists, or other products intended for weight loss, including prescription drugs, over-the-counter drugs, or herbal products. Wegovy has not been studied in patients with a history of pancreatitis.

The safety and efficacy of Wegovy were studied in four 68-week trials. Three were randomized, double-blind, placebo-controlled trials including 16 weeks of dose increases and one was a double-blind, placebo-controlled, randomized withdrawal trial in which patients receiving Wegovy either continued with the treatment or switched to a placebo. More than 2,600 patients received Wegovy for up to 68 weeks in these four studies and more than 1,500 patients received a placebo. The largest placebo-controlled trial enrolled adults without diabetes. The average age at the start of the trial was 46 years and 74% of patients were female. The average body weight was 231 pounds 105 kg and the average BMI was 38 kg/m2. Individuals who received Wegovy lost an average of 12.4% of their initial body weight compared to individuals who received a placebo. Another trial enrolled adults with type 2 diabetes. The average age was 55 years and 51% were female. The average body weight was 220 pounds 100 kg and the average BMI was 36 kg/m2. In this trial, individuals who received Wegovy lost 6.2% of their initial body weight compared to those who received a placebo.

The FDA states that Wegovy is indicated for chronic weight management in patients with a body mass index (BMI) of 27 kg/m2 or greater who have at least one weight-related ailment or in patients with a BMI of 30 kg/m2 or greater. While individual results may vary, Wegovy has been shown to be effective at helping individuals lose up to 12.4% of their initial body weight without diabetes and up to 6.2% of their initial body weight with type 2 diabetes.

The FDA states that Wegovy is indicated for chronic weight management, and the speed of weight loss will depend on the individual. The FDA recommends that Wegovy is used in combination with a reduced calorie diet and increased physical activity.

To qualify for Wegovy, you must be at least 18 years of age with a BMI of 27 or higher with at least one weight-related condition or a BMI of 30 or higher. You must also be committed to a reduced-calorie diet and increased physical activity. You can book an appointment or give us a call to see if you qualify.

Wegovy has been shown to be effective in helping individuals lose up to 12.4% of their initial body weight without diabetes and up to 6.2% of their initial body weight with type 2 diabetes. The FDA recommends that Wegovy is used in combination with a reduced calorie diet and increased physical activity. If a patient is motivated and committed to weight loss and is willing to follow the FDA-recommended combination of Wegovy and diet and exercise, then Wegovy may be worth it for weight loss.

The cost of Wegovy per month will vary depending on a patient’s insurance coverage. Most insurance companies will cover Wegovy for weight loss, but patients should speak to their healthcare provider to get an estimate of the monthly cost.

Wegovy should be taken in combination with a reduced-calorie diet and increased physical activity. While individual results may vary, Wegovy has been shown to be effective in helping individuals lose up to 12.4% of their initial body weight without diabetes and up to 6.2% of their initial body weight with type 2 diabetes.

Wegovy works by mimicking a hormone called glucagon-like peptide-1 (GLP-1) that targets areas of the brain that regulate appetite and food intake. The medication dose must be increased gradually over 16 to 20 weeks to 2.4 mg once weekly to reduce gastrointestinal side effects. Wegovy should not be used in combination with other semaglutide-containing products, other GLP-1 receptor agonists, or other products intended for weight loss, including prescription drugs, over-the-counter drugs, or herbal products.

Wegovy is indicated for chronic weight management, and while individual results may vary, Wegovy has been shown to be effective in helping individuals lose up to 12.4% of their initial body weight without diabetes and up to 6.2% of their initial body weight with type 2 diabetes. Wegovy has not been studied specifically for reducing belly fat, but it has been shown to be effective for weight loss in general.

The speed of weight loss will depend on the individual. While individual results may vary, Wegovy has been shown to be effective in helping individuals lose up to 12.4% of their initial body weight without diabetes and up to 6.2% of their initial body weight with type 2 diabetes.

Yes, Wegovy is indicated for chronic weight management in adults with obesity or overweight with at least one weight-related condition without diabetes. The FDA recommends that Wegovy is used in combination with a reduced calorie diet and increased physical activity.

Yes, Wegovy is indicated for chronic weight management in adults with obesity or overweight with at least one weight-related condition without diabetes. The FDA recommends that Wegovy is used in combination with a reduced calorie diet and increased physical activity.

The most common side effects of Wegovy include nausea, diarrhea, vomiting, constipation, abdominal stomach pain, headache, fatigue, dyspepsia indigestion, dizziness, abdominal distension, eructation belching, hypoglycemia low blood sugar in patients with type 2 diabetes, flatulence gas buildup, gastroenteritis an intestinal infection and gastroesophageal reflux disease a type of digestive disorder.

Wegovy is a once-weekly injection, not an oral medication. Wegovy is indicated for chronic weight management in adults with obesity or overweight with at least one weight-related condition without diabetes. The FDA recommends that Wegovy is used in combination with a reduced calorie diet and increased physical activity.

Wegovy Semaglutide injection is a once-weekly injection indicated for chronic weight management in adults with obesity or overweight with at least one weight-related condition. It has been shown to be effective in helping individuals lose up to 12.4% of their initial body weight without diabetes and up to 6.2% of their initial body weight with type 2 diabetes. The cost of Wegovy per month will vary depending on a patient’s insurance coverage. The FDA recommends that Wegovy is used in combination with a reduced calorie diet and increased physical activity. If a patient is motivated and committed to weight loss and is willing to follow the FDA-recommended combination of Wegovy and diet and exercise, then Wegovy may be worth it for weight loss.

You can book your appointment for your Wegovy/Semaglutide consultation at Beyond Healthy MD now.